ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2015
SOX 1, contrary to SOX 2, suppresses proliferation, migration, and invasion in human laryngeal squamous cell carcinoma by inhibiting the Wnt/β-catenin pathway.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 14 citations in OpenAlex.
- A cutting-edge investigation of the multifaceted role of SOX family genes in cancer pathogenesis through the modulation of various signaling pathways.Functional & integrative genomics · 2025Review
- KLK11 acts as a tumor-inhibitor in laryngeal squamous cell carcinoma through the inactivation of Akt/Wnt/β-catenin signaling.Journal of bioenergetics and biomembranes · 2021Article
- SPOCK1: a multi-domain proteoglycan at the crossroads of extracellular matrix remodeling and cancer development.American journal of cancer research · 2020Review
- LncRNA UCA1 promotes cell proliferation, invasion and migration of laryngeal squamous cell carcinoma cells by activating Wnt/β-catenin signaling pathway.Experimental and therapeutic medicine · 2019Article
- Oncogenic activity of SOX1 in glioblastoma.Scientific reports · 2017Article
- Artemin promotes proliferation and metastasis in human laryngeal squamous cell carcinoma.International journal of clinical and experimental pathology · 2017Article
- LncRNA MNX1-AS1 Contributes to Laryngeal Squamous Cell Carcinoma Growth and Migration by Regulating mir-744-5p/bcl9/β-Catenin Axis.Cell transplantationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sex-determining region Y (SRY)-box protein 1 (SOX 1) has been reported to have the inhibiting effects on various cancer cells; however, the expression and effect of SOX 1 on laryngeal squamous cell carcinoma (LSCC) have not been determined. Therefore, the aim of this study was to assess the anti-proliferation and metastatic effects of SOX 1 and its related mechanisms on LSCC. According to our present study, first, we found that overexpression of SOX 1 could significantly inhibit proliferation and promote apoptosis in Tu212 cells. Additionally, overexpression of SOX 1 suppressed the migration and invasion potential of Tu212 cells via regulating Wnt/β-catenin pathway. Finally, we demonstrated for the first time that overexpression of SOX 1 could downregulate the expression of SOX 2, and co-expression of SOX 1 and SOX 2 could reverse the anti-tumor effect of SOX 1. In conclusion, our studies suggested that SOX 1 suppressed cell growth and invasion in Tu212 cells by inhibiting Wnt/β-catenin pathway, and the anti-tumor effect of SOX 1 could be weakened by SOX 2, which may be a potential molecular basis for clinical treatment of LSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.